Building on Chiba and Hokkaido university research, Think-Lands is aiming to commercialise microneedles manufactured with its optical vortex production system.
Think-Lands, a Japan-based microneedle manufacturer based on research from Chiba and Hokkaido universities, has obtained approximately ¥340m ($3m) in an equity and debt round featuring drug manufacturing contractor CMIC CMO, according to the Venture Times.
CMIC CMO took up equity alongside dental software developer Dof, seed-stage VC vehicle Real Tech Fund and investment firm AIS Capital, while Resona Bank agreed to supply Think Lands with a loan of undisclosed size.
Founded in 2014, Think-Lands is working on a manufacturing technology for producing hollow microscopic needles that would facilitate the painless administration of medical and cosmetic products currently injected through a long hypodermic needle.
The microneedles are manufactured by using a so-called optical vortex laser production system developed by Chiba and Hokkaido researchers that allows greater flexibility in design than alternative techniques.
Think-Lands will use the capital to fund the commercialisation of its microneedle products through means including a strategic partnership with CMIC CMO.
The company’s corporate profile indicates it had received approximately $1m in capital prior to the latest round, however further details could not be ascertained.
